Exclusive Summary

• Lansoprazole's global originator patents have expired with zero IP barriers, enabling immediate cross-border distribution partnerships without legal delay.
• A massive global patient base suffering from peptic ulcers and acute GI bleeding drives a rigid, high-volume demand for intravenous PPIs in Emergency Centers and ICUs.
• Endorsed as a golden-standard first-line treatment for severe GI bleeding by international guidelines, the 30mg specification perfectly aligns with standard single-dose clinical protocols.
• Supported by an advanced sterile lyophilized supply chain, comprehensive CTD-format dossiers can be provided to aggressively accelerate local regulatory approvals for distributors.
• Significant economies of scale and API-to-finished integrated cost advantages guarantee highly lucrative distributor margins and maximizing hit-rates in public hospital procurement tenders.